4.5 Article

Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non-small cell lung cancer patients

Journal

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 87, Issue 4, Pages 2098-2110

Publisher

WILEY
DOI: 10.1111/bcp.14621

Keywords

drug– drug interaction; gefitinib; ningetinib; transporters

Funding

  1. Guangdong Innovative and Entrepreneurial Research Team Program [2016ZT06Y616]
  2. Strategic Priority Research Program of the Chinese Academy of Science [12050306]
  3. General Program of National Natural Science Foundation of China [82073924]

Ask authors/readers for more resources

The study aimed to investigate the drug interaction of ningetinib and gefitinib in NSCLC patients, as well as the mechanism of high plasma exposure of N-demethylated ningetinib (M1). The results showed that co-administration of ningetinib with gefitinib reduced the plasma exposure of M1 by 80%, and CYP1A1 was primarily responsible for M1 formation. In addition, M1 was identified as a substrate of P-gp and BCRP efflux transporters, with ningetinib and gefitinib being their inhibitors.
Aims Ningetinib is a tyrosine kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC). The present study aims to investigate the drug interaction of ningetinib and gefitinib and the mechanism of high plasma exposure of N-demethylated ningetinib (M1) in NSCLC patients. Methods Patients with NSCLC were recruited. Metabolism and transport assays were performed using in vitro models. Deuterated M1 was used to study the effects of ningetinib and gefitinib on M1 efflux in Institute of Cancer Research (ICR) mice. Results Upon co-administration of ningetinib with gefitinib, the plasma exposure of M1 was reduced by 80%, whereas that of ningetinib was not affected. In vitro experiments indicated that CYP1A1 was primarily responsible for M1 formation. Gefitinib was demonstrated to be a strong inhibitor of CYP1A1 with K-i value of 0.095 mu M. M1 was identified as a substrate of efflux transporters P-gp and BCRP, while ningetinib and gefitinib were demonstrated to be their inhibitors, which was consistent with the results in mice. However, the inhibitory effect of gefitinib on efflux in vivo was negligible in the presence of ningetinib. Conclusion The high plasma exposure of M1 in patients was attributed to the inhibition of M1 efflux by ningetinib and its low tissue affinity. When co-administered, gefitinib inhibited the formation of M1, but due to the low metabolic yield of M1 in vivo, the pharmacokinetics of ningetinib was not influenced. Inhibition of CYP1A1 may increase the concentration of ningetinib in target tissues, and the long-term safety and efficacy of ningetinib combined with gefitinib should be evaluated.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available